San Diego-dependent Viking Therapeutics marked alone as a significant competitor inside the weight loss drug sector in February following revealing promising data from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given like a weekly injection As well as in March the compan